drugset / Trial / NCT00902226

Escitalopram in Patients With Social Anxiety Disorder

NCT00902226

Phase 4 Completed 30 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

Timeline

Start
2009-03
Primary completion
2009-12
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 5 mg Oral
Subject Escitalopram Small molecule 20 mg Oral

Indications